Year All 2026 2025 2024 2023 October 8, 2026 Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026 October 5, 2026 Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team September 24, 2026 Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment September 1, 2026 Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference August 10, 2026 Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance August 10, 2026 Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures July 28, 2026 Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome July 14, 2026 Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026 July 13, 2026 Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases July 10, 2026 Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
October 8, 2026 Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
October 5, 2026 Alamar Biosciences Names Former Grail CEO Bob Ragusa to Board of Directors and Expands Leadership Team
September 24, 2026 Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
September 1, 2026 Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
August 10, 2026 Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance
August 10, 2026 Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures
July 28, 2026 Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
July 13, 2026 Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases
July 10, 2026 Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
